Search results for "oncogene"

showing 10 items of 1005 documents

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

2015

KRAS mutation has been reported as a marker of radio-resistance in rectal cancer and unfavourable outcome in both colon and rectal cancer. This study suggests that a single-nucleotide polymorphism of the KRAS gene (LCS-6 variant) may predict response to neoadjuvant treatment and mitigate the poor prognosis associated with KRAS mutation in locally advanced rectal cancer.

MaleOncologyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLET-7 MICRORNA-BINDINGCetuximabmedicine.disease_causeCOLORECTAL-CANCER3'-UNTRANSLATED REGION0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsRectal cancerNeoadjuvant therapySingle-nucleotide polymorphism0303 health sciencesCetuximabCOLON-CANCERHazard ratioCAPOX RegimenChemoradiotherapyHematologysingle-nucleotide polymorphismMiddle AgedCombined Modality TherapyNeoadjuvant TherapyBINDING SITE POLYMORPHISM3. Good healthOxaliplatinLet-7Oncology030220 oncology & carcinogenesis5-FLUOROURACIL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleKRASLife Sciences & Biomedicinemedicine.drugAdultGenetic Markersmedicine.medical_specialtyGenotypeLCS-6 KRAS variantPolymorphism Single NucleotideDisease-Free SurvivalCLINICAL-TRIALProto-Oncogene Proteins p21(ras)03 medical and health sciencesSDG 3 - Good Health and Well-beinglet-7Internal medicineGastrointestinal TumorsBiomarkers TumorKRASmedicineHumansOncology & CarcinogenesisProgression-free survivalrectal cancerneoplasmsCapecitabineAged030304 developmental biologyCancer och onkologiScience & TechnologyRectal Neoplasmsbusiness.industryOriginal Articlesmedicine.diseasedigestive system diseasesMicroRNAsCancer and Oncologybusiness1112 Oncology And CarcinogenesisChemoradiotherapyRASAnnals of Oncology
researchProduct

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

2012

Background: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates. Methodology/Principal Findings: KRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy da…

MaleOncologyOrganoplatinum Compoundsendocrine system diseasesEpidemiologyColorectal cancer:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]DeoxycytidineMetastasis:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Antineoplastic Combined Chemotherapy ProtocolsPathologyMedicineNeoplasm Metastasisgeneslcsh:Sciencemediana edad:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [Medical Subject Headings]Aged 80 and overanciano:Chemicals and Drugs::Organic Chemicals::Organometallic Compounds::Organoplatinum Compounds [Medical Subject Headings]Cancer Risk FactorsClinical Pharmacologyprotocolos de quimioterapia antineoplásica combinadaColon AdenocarcinomaPronósticoCombination chemotherapyadultoPrognosisBevacizumabOxaliplatinpronósticoOncologyMedicineOncology Agentsmedicine.medical_specialty:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]FluorouraciloBevacizumab:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Cytidine::Deoxycytidine [Medical Subject Headings]:Check Tags::Male [Medical Subject Headings]Molecular GeneticsCapecitabine:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies Monoclonal::Antibodies Monoclonal Humanized [Medical Subject Headings]Gastrointestinal TumorsGenetics:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]HumansClinical TrialsBiologyneoplasmsCapecitabineAgedlcsh:R:Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings]:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes Neoplasm::Oncogenes::Proto-Oncogenes::Genes ras [Medical Subject Headings]medicine.diseasedigestive system diseasesOxaliplatin:Check Tags::Female [Medical Subject Headings]PharmacogeneticsMutationlcsh:QfluorouraciloMultivariate analysisDesoxicitidinahumanosCancer Treatment:Named Groups::Persons::Age Groups::Adult::Aged::Aged 80 and over [Medical Subject Headings]lcsh:Medicinemedicine.disease_causeNeoplasias colorrectalesSurgical oncologyBasic Cancer Research:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Pyrimidinones::Uracil::Fluorouracil [Medical Subject Headings]Clinical Trials (Cancer Treatment)metástasis neoplásicaMetástasis neoplásicaMultidisciplinaryMiddle AgedGenetic EpidemiologyProtocolos de quimioterapia antineoplásica combinadaFemaleAntiangiogenesis TherapyFluorouracilKRASColorectal NeoplasmsResearch Articlemedicine.drugAdultDrugs and DevicesClinical Pathologyneoplasias colorrectalesClinical Research DesignGenetic Causes of CancerAntibodies Monoclonal HumanizedAntibodiesRectal CancerAntibody TherapyDiagnostic MedicineInternal medicine:Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]mutaciónClinical GeneticsMutaciónbusiness.industryPharmacoepidemiologyCancers and NeoplasmsHuman GeneticsChemotherapy and Drug TreatmentdesoxicitidinaGenes rasanticuerposGenetics of Diseasebusinesscompuestos organoplatinoPLoS ONE
researchProduct

Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Speci…

2005

Abstract Purposes: To elucidate the prognostic value of the immunohistochemical (IHC) expression of Bcl-2, Bax, Cox-2 and Ki-67 antigen in biopsy cores (C) and surgical specimens (SP) of prostate cancer (PC) and to determine the C to SP reproducibility. Material and methods: The IHC study was carried out in 91 patients operated by means of radical prostatectomy (RP) with available formalin-fixed paraffin-embedded material from both C and SP. Results: The IHC expression of Bcl-2 in C and SP was very low (5%). Bax was expressed in almost all the patients and did not show any prognostic value. We observed a good reproducibility between C and SP for all molecules except with Bax. In prostate C,…

MaleOncologymedicine.medical_specialtyPathologyBiopsyUrologymedicine.medical_treatmentDisease-Free SurvivalProstate cancerProstateInternal medicineBiopsyBiomarkers TumormedicineHumansAgedRetrospective Studiesbcl-2-Associated X ProteinProstatectomyUnivariate analysismedicine.diagnostic_testbiologyProstatectomybusiness.industryMembrane ProteinsProstatic NeoplasmsAnatomical pathologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistryKi-67 Antigenmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2Cyclooxygenase 2Ki-67Multivariate AnalysisDisease Progressionbiology.proteinImmunohistochemistrybusinessEuropean Urology
researchProduct

Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.

2010

BACKGROUND & AIMS: The limited clinical response observed in many patients with colorectal cancer may be related to the presence of chemoresistant colorectal can- cer stem cells (CRC-SCs). Bone morphogenetic protein 4 (BMP4) promotes the differentiation of normal colonic stem cells. We investigated whether BMP4 might be used to induce differentiation of CRC-SCs and for therapeutic purposes. METHODS: CRC-SCs were isolated from 25 tumor samples based on expression of CD133 or using a selection culture medium. BMP4 expression and activity on CRC-SCs were evaluated in vitro; progeny of the stem cells were evaluated by immunofluorescence, immuno- blot, and flow cytometry analyses. The potential …

MaleOrganoplatinum CompoundsCellular differentiationDrug ResistanceApoptosisBone Morphogenetic Protein 4Colon Cancer; Drug Resistance; Neoplasia; Tumor Resistance to Chemotherapy; AC133 Antigen; Adenomatous Polyposis Coli; Aged; Aged 80 and over; Animals; Antigens CD; Antineoplastic Agents; Apoptosis; Bone Morphogenetic Protein 4; Cell Differentiation; Cells Cultured; Colorectal Neoplasms; Female; Fluorouracil; Glycoproteins; Humans; Male; Mice; Microsatellite Instability; Middle Aged; Mutation; Neoplastic Stem Cells; Organoplatinum Compounds; PTEN Phosphohydrolase; Peptides; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Smad4 Protein; GastroenterologyMice80 and overBone morphogenetic protein receptorAC133 AntigenCells CulturedSmad4 ProteinAged 80 and overCulturedColon Cancerintegumentary systemGastroenterologyCell DifferentiationBMP4 colon stem cellsMiddle AgedCDOxaliplatinTumor Resistance to ChemotherapyBone morphogenetic protein 4Adenomatous Polyposis Coliembryonic structuresNeoplastic Stem CellsFemaleMicrosatellite InstabilityFluorouracilStem cellColorectal Neoplasmsanimal structuresCellsAntineoplastic AgentsBiologyBone morphogenetic proteinSettore MED/04 - PATOLOGIA GENERALECancer stem cellAntigens CDPTENAnimalsHumansAntigensneoplasmsPI3K/AKT/mTOR pathwayAgedGlycoproteinsNeoplasiaHepatologyPTEN Phosphohydrolasedigestive system diseasesMutationCancer researchbiology.proteinPhosphatidylinositol 3-KinasePeptidesProto-Oncogene Proteins c-aktGastroenterology
researchProduct

Risk Profiles and Penetrance Estimations in Multiple Endocrine Neoplasia Type 2A Caused by Germline RET Mutations Located in Exon 10

2010

Multiple endocrine neoplasia type 2 is characterized by germline mutations in RET. For exon 10, comprehensive molecular and corresponding phenotypic data are scarce. The International RET Exon 10 Consortium, comprising 27 centers from 15 countries, analyzed patients with RET exon 10 mutations for clinical-risk profiles. Presentation, age-dependent penetrance, and stage at presentation of medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism were studied. A total of 340 subjects from 103 families, age 4-86, were registered. There were 21 distinct single nucleotide germline mutations located in codons 609 (45 subjects), 611 (50), 618 (94), and 620 (151). MTC was present…

MalePHEOCHROMOCYTOMAendocrine system diseasesMEDULLARY-THYROID CARCINOMAAdrenal Gland NeoplasmsMultiple Endocrine Neoplasia Type 2aPenetrancemedicine.disease_causePHENOTYPEGermlineExon0302 clinical medicinemedullary thyroid carcinomaMEN2BMEN2AChildGenetics (clinical)GeneticsAged 80 and overMutationHyperparathyroidismLife SciencesExonsMiddle AgedCARRIERSPenetranceCANCERPROPHYLACTIC THYROIDECTOMY3. Good healthgenotype-phenotypeFAMILYMEN2030220 oncology & carcinogenesisChild PreschoolFemaleAdultAdolescent030209 endocrinology & metabolismMultiple endocrine neoplasia type 2BiologyPheochromocytoma03 medical and health sciencesYoung AdultGermline mutationGeneticsmedicineHumansThyroid NeoplasmsCodonGerm-Line MutationAgedNeoplasm StagingProto-Oncogene Proteins c-retCancerHIRSCHSPRUNG-DISEASEPROTOONCOGENEmedicine.diseaseGENECarcinoma NeuroendocrineCancer researchRETHuman Mutation
researchProduct

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

2015

// Bruno Vincenzi 1 , Chiara Cremolini 2 , Andrea Sartore-Bianchi 3 , Antonio Russo 4 , Francesco Mannavola 5 , Giuseppe Perrone 6 , Francesco Pantano 1 , Fotios Loupakis 2 , Daniele Rossini 2 , Elena Ongaro 7 , Erica Bonazzina 3 , Emanuela Dell’Aquila 1 , Marco Imperatori 1 , Alice Zoccoli 1 , Giuseppe Bronte 4 , Giovanna De Maglio 7 , Gabriella Fontanini 8 , Clara Natoli 9 , Alfredo Falcone 2 , Daniele Santini 1 , Andrea Onetti-Muda 6 , Salvatore Siena 3 , Giuseppe Tonini 1 and Giuseppe Aprile 7 1 Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy 2 Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy 3 Niguarda Cancer Center, Osped…

MalePathologyColorectal cancerSettore MED/06 - Oncologia MedicaColorectal NeoplasmRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturededucation.field_of_studyUnivariate analysisBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; OncologyLiver NeoplasmsMiddle AgedPrognosisBevacizumabSurvival RateOncologyLiver NeoplasmCohortFemaleK-Ras; mutation rate; colorectal cancer; bevacizumab; prognosisColorectal NeoplasmsK-RasResearch Papermedicine.drugHumanmedicine.medical_specialtyBevacizumabPrognosiMutation ratePopulationBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Rate; Tumor Cells Cultured; OncologyReal-Time Polymerase Chain ReactionFollow-Up StudieProto-Oncogene Proteins p21(ras)Internal medicinemedicineHumanseducationSurvival rateRetrospective StudiesNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerRetrospective cohort studymedicine.diseaseColorectal cancerK-RaMutationbusinessFollow-Up Studies
researchProduct

Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers.

2005

Aims:  To evaluate the clinicopathological and immunohistochemical characteristics of Merkel cell carcinoma (MCC) in an attempt to find new, potentially significant, prognostic markers. Methods and results:  Clinical data and follow-up, histopathological features (pattern, cell size, thickness, mitoses, vascular invasion, lymphocytic infiltration) and immunohistochemical detection [CK20, thyroid transcription factor (TTF-1), chromogranin A, synaptophysin, p53, Ki67, Fli-1, CD99, c-Kit] were evaluated in 20 cases of MCC. Fli-1 and CD99 were detected in 90% and 55% of cases, respectively. Tumour size > 30 mm, stage II, ‘absent’ lymphocytic infiltration, and the presence of > 50% of Ki67+ tumo…

MalePathologyThyroid Nuclear Factor 1Keratin-20Intermediate Filament ProteinsLymph nodeAged 80 and overbiologyMerkel cell carcinomaChromogranin ANuclear ProteinsGeneral MedicineMiddle AgedPrognosisImmunohistochemistryDNA-Binding ProteinsProto-Oncogene Proteins c-kitmedicine.anatomical_structureFemaleMerkel cellmedicine.medical_specialtyHistologyCD99Synaptophysin12E7 AntigenPathology and Forensic MedicineAntigens CDProto-Oncogene ProteinsCarcinomamedicineBiomarkers TumorChromograninsHumansSurvival analysisAgedNeoplasm StagingProto-Oncogene Protein c-fli-1Keratin 20medicine.diseaseSurvival AnalysisCarcinoma Merkel CellMicroscopy ElectronKi-67 AntigenMultivariate Analysisbiology.proteinTrans-ActivatorsChromogranin ANeoplasm Recurrence LocalTumor Suppressor Protein p53Cell Adhesion MoleculesFollow-Up StudiesTranscription FactorsHistopathology
researchProduct

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

2014

BRAF-V600E expression is identified in hematopoietic progenitor and precursor myeloid dendritic cells in patients with high-risk LCH, and enforced expression of BRAF-V600E in CD11c+ cells recapitulates a high-risk LCH-like phenotype in mice.

MalePathologyendocrine system diseasesCellular differentiationCD34Antigens CD34Mice0302 clinical medicineLangerhans cell histiocytosisBone MarrowRisk FactorsImmunology and Allergyskin and connective tissue diseasesChild0303 health sciencesCell Differentiation3. Good healthHistiocytosismedicine.anatomical_structurePhenotypeTreatment Outcome030220 oncology & carcinogenesisChild PreschoolAntigens Surface2723 Immunology and AllergyFemaleProto-Oncogene Proteins B-rafmedicine.medical_specialtyImmunologyCD11c610 Medicine & healthBiologyArticle03 medical and health sciencesGermline mutationmedicineAnimalsHumansCell LineageGenetic Predisposition to DiseaseLectins C-TypeProgenitor cellneoplasms030304 developmental biology2403 ImmunologyHistocompatibility Antigens Class II302InfantCorrectionDendritic Cellsmedicine.diseaseHematopoietic Stem Cellsdigestive system diseasesCD11c Antigenenzymes and coenzymes (carbohydrates)Histiocytosis Langerhans-CellMannose-Binding Lectins10032 Clinic for Oncology and HematologyMutationBone marrowThe Journal of experimental medicine
researchProduct

Research of cardiomyocyte precursors in adult rat heart

2006

Recent reports supported the existence of stem cells in adult hearts. However, phenotype and localization of these cells have not been completely described and it is unknown if cardiac regenerative potential differs from one subject to another. The aims of our work were to identify different populations of cardiac stem cells by the analysis of specific markers and to evaluate the expression variability of these markers in 12 adult rat hearts. The expression of CD9, taube nuss and nanog suggests the presence of stem cells from the earliest stages of embryogenesis in adult myocardium. Their different expression could be associated to the degree of stem cell differentiation. CD34 and c-Kit ant…

MalePathologymedicine.medical_specialtyCellular differentiationAntigens CD34Nerve Tissue ProteinsBiologyNestinStem cells heart expression rat.Intermediate Filament ProteinsmedicineAnimalsCell LineageMyocytes CardiacAntigensRats WistarStem cell transplantation for articular cartilage repairInduced stem cellsMyocardiumStem CellsEndothelial CellsCell DifferentiationAmniotic stem cellsCell BiologyGeneral MedicineGATA4 Transcription FactorRatsEndothelial stem cellProto-Oncogene Proteins c-kitAmniotic epithelial cellsStem cellDevelopmental BiologyAdult stem cellTissue and Cell
researchProduct

DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex.

2005

Mutations in DJ-1 gene have been recently shown to cause autosomal recessive early-onset Parkinson’s disease (EOPD) in a large Dutch family and in a small consanguineous Italian family.1 Subsequent to this initial finding, several additional DJ-1 mutations were identified in subjects with EOPD.2–6 We describe a family from southern Italy with three brothers affected by a complex disorder characterized by early-onset parkinsonism-dementia-amyotrophic lateral sclerosis (EOPD-D-ALS). The analysis of the DJ-1 gene showed a novel homozygous mutation (E163K) in exon 7 and a novel homozygous mutation (g.168_185dup) in the promoter region of this gene in living affected subjects

MalePathologymedicine.medical_specialtyDNA Mutational AnalysisProtein Deglycase DJ-1Glutamic AcidGene mutationParkinsonismmedicine.disease_causeDISEASEPARK7GUAMExonMucoproteinsDegenerative diseaseParkinsonian DisordersmedicineHumansDementiaRNA MessengerAmyotrophic lateral sclerosisGeneFamily HealthOncogene ProteinsGeneticsMutationReverse Transcriptase Polymerase Chain Reactionbusiness.industryParkinsonismAmyotrophic Lateral SclerosisIntracellular Signaling Peptides and ProteinsExonsDEGENERATIONBlotting Northernmedicine.diseaseGENEINCLUSIONSNeurologyMutationAmyotrophic LateralFemaleDementiaNeurology (clinical)TAUbusiness
researchProduct